Evaluation of Metabolic Risk Marker in Obesity-related Glomerulopathy

Journal of Renal Nutrition

Volumn 21, Issue 4, 2011, Pages 309-315

  Chen, Hui Mei ^a   Chen, Yan ^a   Zhang, Yi De ^a   Zhang, Pei Pei ^a   Chen, Hui Ping ^a   Wang, Qing Wen ^a   Li, Lei Shi ^a   Liu, Zhi Hong ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; BIOLOGICAL MARKER; INSULIN;

ADULT; ARTICLE; BLOOD; BODY COMPOSITION; BODY MASS; CROSS-SECTIONAL STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; KIDNEY DISEASE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; PATHOLOGY; PROTEINURIA; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY COMPOSITION; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; FEMALE; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; ISLET AMYLOID POLYPEPTIDE; KIDNEY DISEASES; LINEAR MODELS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; PROTEINURIA; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 79959189494     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2010.06.019     Document Type: Article

References (37)

1. Bambs C., Cerda J., Escalona A. Morbid obesity in a developing country: the Chilean experience. Bull World Health Organ 2008, 86:813-814.
2. Bekedam H. The challenge of obesity and related disease control in China. Obes Rev 2008, 9:4-5.
3. Chen C.M. Overview of obesity in Mainland China. Obes Rev 2008, 9:14-21.
4. Chen H.M., Li S.J., Chen H.P., et al. Obesity-related glomerulopathy in China: a case series of 90 patients. Am J Kidney Dis 2008, 52:58-65.
5. Kambham N., Markowitz G.S., Valeri A.M., et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001, 59:1498-1509.
6. Shen WW, Chen HM, Chen H, et al: Obesity-related glomerulopathy: body mass index and proteinuria. Clin J Am Soc Nephrol (in press).
7. Wahba I.M., Mak R.H. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol 2007, 2:550-562.
8. Bevier W.C., Zisser H., Palerm C.C., et al. Calculating the insulin to carbohydrate ratio using the hyperinsulinaemic-euglycaemic clamp-a novel use for a proven technique. Diabetes Metab Res Rev 2007, 23:472-478.
9. Dixon J.B., O'Brien P. A disparity between conventional lipid and insulin resistance markers at body mass index levels greater than 34 kg/m(2). Int J Obes Relat Metab Disord 2001, 25:793-797.
10. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
11. Jones C.N., Abbasi F., Carantoni M., et al. Roles of insulin resistance and obesity in regulation of plasma insulin concentrations. Am J Physiol Endocrinol Metab 2000, 278:E501-E508.
12. Sainaghi P.P., Castello L., Bergamasco L., et al. Metabolic characteristics of glucose intolerance: the critical role of obesity. Exp Clin Endocrinol Diabetes 2008, 116:86-93.
13. Cooper G.J., Willis A.C., Clark A., et al. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A 1987, 84:8628-8632.
14. Castle A.L., Kuo C.H., Ivy J.L. Amylin influences insulin-stimulated glucose metabolism by two independent mechanisms. Am J Physiol 1998, 274:E6-E12.
15. Ritz E., Wanner C. Lipid abnormalities and cardiovascular risk in renal disease. J Am Soc Nephrol 2008, 19:1065-1070.
16. Elbein S.C., Rasouli N. Intermuscular lipid: a marker of disordered fat partitioning or the consequence of obesity?. Am J Clin Nutr 2008, 87:1585-1586.
17. McLaughlin T., Abbasi F., Cheal K., et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003, 139:802-809.
18. Gatti A., Morini E., Cosmo S.D., et al. Metabolic syndrome is not a risk factor for kidney dysfunction in obese non-diabetic subjects. Obesity (Silver Spring) 2008, 16:899-901.
19. Chen H.M., Liu Z.H., Zeng C.H., et al. Podocyte lesions in patients with obesity-related glomerulopathy. Am J Kidney Dis 2006, 48:772-779.
20. Zhou B.F. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults-study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomed Environ Sci 2002, 15:83-96.
21. Lemann J., Bidani A.K., Bain R.P., et al. Use of the serum creatinine to estimate glomerular filtration rate in health and early diabetic nephropathy. Collaborative Study Group of Angiotensin Converting Enzyme Inhibition in Diabetic Nephropathy. Am J Kidney Dis 1990, 16:236-243.
22. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care 2004, 27:1487-1495.
23. Hall J.E., Crook E.D., Jones D.W., et al. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002, 324:127-137.
24. Chen H., Liu Z., Li S., et al. The relationship between body fat distribution and renal damage in Chinese with obesity. Exp Clin Endocrinol Diabetes 2008, 116:99-103.
25. Ikee R., Hamasaki Y., Oka M., et al. Glucose metabolism, insulin resistance, and renal pathology in non-diabetic chronic kidney disease. Nephron Clin Pract 2008, 108:c163-c168.
26. Koch M., Beien A., Fussha Ller A., et al. Impact of age, body mass index, insulin resistance and proteinuria on the kidney function in obese patients with Type 2 diabetes and renal insufficiency. Clin Nephrol 2008, 69:10-17.
27. Ma F., Qiao L., Yue H., et al. Homeostasis model assessment-insulin resistance (HOMA-IR), a key role for assessing the ovulation function in polycystic ovary syndrome (PCOS) patients with insulin resistance. Endocr J 2008, 55:943-945.
28. Vogeser M., Konig D., Frey I., et al. Fasting serum insulin and the homeostasis model of insulin resistance (HOMA-IR) in the monitoring of lifestyle interventions in obese persons. Clin Biochem 2007, 40:964-968.
29. Kahn S.E., Hull R.L., Utzschneider K.M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006, 444:840-846.
30. Ludvik B., Kautzky-Willer A., Prager R., et al. Amylin: history and overview. Diabet Med 1997, 14(Suppl 2):S9-S13.
31. Watschinger B., Hartter E., Traindl O., et al. Increased levels of plasma amylin in advanced renal failure. Clin Nephrol 1992, 37:131-134.
32. Vine W., Smith P., LaChappell R., et al. Effects of rat amylin on renal function in the rat. Horm Metab Res 1998, 30:518-522.
33. Zhang S., Liu J., Saafi E.L., et al. Induction of apoptosis by human amylin in RINm5F islet beta-cells is associated with enhanced expression of p53 and p21WAF1/CIP1. FEBS Lett 1999, 455:315-320.
34. Peng A., Liu Z.H., Zhou H., et al. Amylin induces apoptosis of cultured human mesangial cells. J Nephrol Dialy Transplant 2002, 11:541-546.
35. Peng A., Liu Z.H., Chen Z.H., et al. Amylin increase permeability and endocytosis of human umbilical endothelial cell in vitro. J Nephrol Dialy Transplant 2004, 13:154-158.
36. Gong W., Liu Z.H., Zeng C.H., et al. Amylin deposition in the kidney of patients with diabetic nephropathy. Kidney Int 2007, 72:213-218.
37. Wang Y., Chen X., Song Y., et al. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int 2008, 73:19-33.